

Supplementary material

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality

Manuelle Viguier,¹ Denis Jullien,^{2,3} Laurent Misery,⁴ Christian Kromer,⁵ Maja Mockenhaupt,⁶ Bhargav Lakshminarasimhan,⁷ Marie Najean,⁷ Nichiren Pillai,⁷ Shah Alam Khan,⁷ Alice B. Gottlieb⁸

1. Université de Reims Champagne-Ardenne, Service de Dermatologie, Hôpital Robert Debré, Reims, France
2. Service de Dermatologie, Hôpital E. Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France
3. Epidermal Immunity & Allergy, Centre International de Recherche en Infectiologie (CIRI), University of Lyon, Lyon, France
4. Department of Dermatology, Venereology and Allergology and French Expert Centre on Pruritus, University Hospital of Brest, Brest, France
5. Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany
6. Department of Dermatology, Dokumentationszentrum schwerer Hautreaktionen (dZh), Medical Center – University of Freiburg, Freiburg, Germany
7. Boehringer Ingelheim International GmbH, Ingelheim, Germany
8. Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA

Corresponding author: Professor Manuelle Viguier; **email:** mviguier@chu-reims.fr

Fig. S1 Key study dates and periods.




Table S1 Patient characteristics

	GPP (N=4,351)	Plaque psoriasis (N=12,945)	General population (N=12,981)
Sex, <i>n</i> (%)			
Male	2,370 (54.5)	7,071 (54.6)	7,094 (54.7)
Female	1,977 (45.4)	5,874 (45.4)	5,887 (45.4)
Age (years), mean (SD)	58.7 (19.7)	58.9 (19.1)	59.5 (19.6)
CCI score, mean (SD)	2.06 (2.45)	1.99 (2.31)	1.98 (2.32)
Region of residence, <i>n</i> (%) ^a			
Ile-De-France	986 (22.7)	2,945 (22.8)	2,950 (22.7)
Auvergne-Rhône-Alpes	474 (10.9)	1,414 (10.9)	1,400 (10.8)
Hauts-De-France	403 (9.3)	1,214 (9.4)	1,212 (9.3)
Nouvelle-Aquitaine	373 (8.6)	1,137 (8.8)	1,110 (8.6)
Occitanie	348 (8.0)	1,029 (7.9)	1,034 (8.0)
Provence-Alpes-Côte D'Azur	339 (7.8)	1,017 (7.9)	1,027 (7.9)

Overseas territories	145 (3.3)	412 (3.2)	380 (2.9)
Other region of France ^b	1,277 (29.3)	3,777 (29.2)	3,868 (29.8)

^aRegion missing for six (0.1%) patients in the GPP cohort.

^bIncludes Bourgogne-Franche-Comte, Bretagne, Centre-Val De Loire, Corse, Grand Est, Normandie, Pays De La Loire.

CCI Charleston Comorbidity Index, *GPP* generalized pustular psoriasis, *SD* standard deviation.

Table S2 Biologic therapies

	GPP	Plaque psoriasis	General population
	(N=4,351)	(N=12,945)	(N=12,981)
Any biologic, <i>n</i> (%)	990 (22.75)	290 (2.24)	44 (0.34)
Ustekinumab	436 (10.02)	66 (0.51)	0
Adalimumab	347 (7.98)	137 (1.06)	22 (0.17)
Secukinumab	285 (6.55)	51 (0.39)	3 (0.02)
Etanercept	201 (4.62)	66 (0.51)	18 (0.14)
Guselkumab	161 (3.70)	28 (0.22)	0
Ixekizumab	152 (3.49)	24 (0.19)	2 (0.02)
Brodalumab	59 (1.36)	8 (0.06)	0
Certolizumab pegol	52 (1.20)	19 (0.15)	9 (0.07)
Tildrakizumab	6 (0.14)	1 (0.01)	0
Infliximab	3 (0.07)	1 (0.01)	0

GPP generalized pustular psoriasis.